Aegis Lifesciences happy to share their presence at Hospitalar 2022

  In posterior fossa tumor resections, Surgi-ORC® Fibril and SURGISPON® play crucial roles in facilitating a successful surgery and promoting optimal patient outcomes. Here's how they contribute to the surgical process: Hemostasis : One of the primary roles of both Surgi-ORC® Fibril and SURGISPON® is to assist in achieving hemostasis, which is the control of bleeding during surgery. Posterior fossa tumor resections can involve intricate procedures near sensitive structures such as the brainstem and cranial nerves, where bleeding must be carefully managed to maintain a clear surgical field and prevent complications. Surgi-ORC® Fibril and SURGISPON® are applied to bleeding surfaces to promote clot formation and minimize bleeding, thus enhancing visibility and surgical precision. Tissue Protection : During posterior fossa tumor resections, it's essential to protect delicate neural tissues from damage during surgical manipulation. Surgi-ORC® Fibril and SURGISPON® act as physical ba...

  At Aegis Lifesciences , we take great pride as Ukrainian Army is using Surgispon to save lives of their soldiers. Surgispon (Absorbable Haemostatic Gelatin Sponge), accelerates the clotting process to achieve haemostasis quickly and effectively in minutes. We are one of the  world’s leading manufacturer & exporter of all major types of Haemostats  – made of Absorbable Gelatin, Oxidized Regenerated Cellulose (ORC) and medical-grade PVA sponges. It leads the industry with its own brand names –  SURGISPON ® ,  SURGI-ORC ® ,  SURGI-PVA TM  &  DENTOSPON ® .

  Aegis Lifesciences plant at Changodar, Ahmedabad, has state-of-the-art manufacturing facility fully equipped with best-in-class machinery to manufacture quality products at a very competitive price. Aegis is in mode of continual improvement and expansion of manufacturing facility to take care of market need for next generation of medical devices. With full-fledged state of art R&D infrastructure, Equipment and Manpower including collaboration activities with reputes Scientific and health care institutions in India and abroad, The R&D is well equipped to meet the requirements from Design, IPR, In-vitro testing, Design transfer meeting the highest standard of Regulatory requirements (ISO 13485: 2016 / Clause 7.2) / MRD, USFDA 510K and 21 CFR). Aegis has been approved the  DSIR accreditation (F.No. TU/ IV – RD/4698/2021) for its R&D  Facility for the activities that had been undertaken in the past and for projects in future. Objectives of the R&D Program Cu...